Nephrogenic systemic fibrosis: A survey of nephrologists' perceptions and practices

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 6, 2010, Pages 964-971

  Abdel Kader, Khaled ^a   Patel, Priti R ^b   Kallen, Alexander J ^b   Sinkowitz Cochran, Ronda L ^b   Bolton, Warren K ^c   Unruh, Mark L ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

ARTICLE; CHRONIC KIDNEY DISEASE; HEALTH CARE POLICY; HUMAN; INTERNET; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROLOGIST; PATIENT CARE; PERCEPTION; PRIVATE PRACTICE; QUESTIONNAIRE; RISK FACTOR; SELF REPORT; UNITED STATES; ATTITUDE TO HEALTH; CLINICAL COMPETENCE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; EVIDENCE BASED MEDICINE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ATTITUDE OF HEALTH PERSONNEL; CLINICAL COMPETENCE; CONTRAST MEDIA; CROSS-SECTIONAL STUDIES; EVIDENCE-BASED MEDICINE; GADOLINIUM; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; LOGISTIC MODELS; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROLOGY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PERCEPTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77953310915     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00140110     Document Type: Article

References (41)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356: 1000-1001, 2000
2. Cowper SE: Nephrogenic systemic fibrosis: The nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46: 763-765, 2005
3. Cowper SE, Bucala R: Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol 25: 358, 2003
4. Ting WW, Stone MS, Madison KC, Kurtz K: Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139: 903-906, 2003 (Pubitemid 36898926)
5. Gibson SE, Farver CF, Prayson RA: Multiorgan involvement in nephrogenic fibrosing dermopathy: An autopsy case and review of the literature. Arch Pathol Lab Med 130: 209-212, 2006 (Pubitemid 43237993)
6. LeBoit PE: What nephrogenic fibrosing dermopathy might be. Arch Dermatol 139: 928-930, 2003
7. Daram SR, Cortese CM, Bastani B: Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis 46: 754-759, 2005
8. Grobner T: Gadolinium - A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108, 2006
9. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362, 2006
10. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56: 137-141, 2007
11. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH: Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort. Radiology 245: 168-175, 2007
12. Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol, 2: 264-267, 2007
13. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN: Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22: 3179-3185, 2007
14. Todd DJ, Kagan A, Chibnik LB, Kay J: Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56: 3433-3441, 2007
15. Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR: Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: A case-control study. Am J Kidney Dis, 51: 966-975, 2008
16. Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA: Gadolinium-based contrast agents and nephrogenic systemic fibrosis: A systematic review and meta-analysis. Nephrol Dial Transplant, 24: 856-863, 2009
17. U.S. Food and Drug Administration. FDA alert: Information for healthcare professionals gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, Multi-Hance, Omniscan, OptiMARK, ProHance). May 23, 2007. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm142884.htm. Accessed September 4, 2009
18. Perazella, MA: Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: The perfect storm. Curr Opin Nephrol Hypertens 18: 519-525, 2009
19. Perazella MA: Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 4: 461-469, 2009
20. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R: Nephrogenic systemic fibrosis: Pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 53: 1621-1628, 2009
21. Weinreb JC, Kuo PH: Nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 17: 159-167, 2009
22. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R: Nephrogenic systemic fibrosis: A mysterious disease in patients with renal failure - Role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2: 258-263, 2007
23. Lind-Ramskov K, Thomsen, HS: Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: A choice between the devil and the deep blue sea for patients with reduced renal function? Acta Radiol 50: 1-3, 2009
24. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA: Nephrogenic systemic fibrosis: Incidence, associations, and effect of risk factor assessment - Report of 33 cases. Radiology 250: 371-377, 2009
25. Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA: MR imaging in patients at risk for developing nephrogenic systemic fibrosis: Protocols, practices, and imaging techniques to maximize patient safety. Radiographics 29: 9-22, 2009
26. Weinreb JC: Impact on hospital policy: Yale experience. J Am Coll Radiol, 5: 53-56, 2008
27. Cowper, SE: Nephrogenic fibrosing dermopathy 2001-2009. Available at http://www.icnfdr.org. Accessed September 4, 2009
28. Martin DR: Nephrogenic system fibrosis: A radiologist's practical perspective. Eur J Radiol 66: 220-224, 2008
29. Sieber MA, Lengsfeld P, Walter J, Schirmer H, Frenzel T, Siegmund F, Weinmann HJ, Pietsch H: Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand. J Magn Reson Imaging 27: 955-962, 2008
30. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt- Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H: Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18: 2164-2173, 2008
31. Broome DR: Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. Eur J Radiol 66: 230-234, 2008
32. Reilly RF: Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3: 747-751, 2008
33. Thomsen, HS: How to avoid nephrogenic systemic fibrosis: Current guidelines in Europe and the United States. Radiol Clin North Am 47: 871-875, vii, 2009
34. Gadolinium-based contrast agents & nephrogenic systemic fibrosis: FDA Briefing Document. Available at http://www.fda. gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ DrugSafetyandRiskManagement-AdvisoryCommittee/UCM190850.pdf. Accessed January 4, 2010
35. Richwine, L: US panel sees higher skin risk with some MRI drugs. Available at http://www.reuters.com/article/ idUSN0813180520091209. Accessed January 4, 2010.
36. Kuo PH: Gadolinium-containing MRI contrast agents: Important variations on a theme for NSF. J Am Coll Radiol 5: 29-35, 2008
37. Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'Malley RB, Parsons DJ, Fuller ER III, Semelka RC: Risk of nephrogenic systemic fibrosis: Evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248: 799-806, 2008
38. Saab G, Abu-Alfa A: Nephrogenic systemic fibrosis - Implications for nephrologists. Eur J Radiol 66: 208-212, 2008
39. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A: Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243: 148-157, 2007
40. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007 (Pubitemid 350074801)
41. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: Approaches and initiatives - A position statement from Kidney Disease Improving Global Outcomes. Kidney Int 72: 247-259, 2007